RESUMO
INTRODUCTION: Anti-sense oligonucleotide (ASO) therapies are a new development in clinical pharmacology offering greater specificity compared to small molecule inhibitors and the ability to target intracellular process' not susceptible to antibody-based therapies. AREAS COVERED: This article reviews the chemical biology of ASOs and related RNA therapeutics. It then reviews the data on their use to treat hyperlipidaemia. Data on mipomersen - an ASO to apolipoprotein B-100(apoB) licensed for treatment of homozygous familial hypercholesterolaemia (FH) is presented. Few effective therapies are available to reduce atehrogenic lipoprotein (a) levels. An ASO therapy to apolipoprotein(a) (ISIS Apo(a)Rx) specifically reduced lipoprotein (a) levels by up to 78%. Treatment options for patients with familial chylomicronaemia syndrome (lipoprotein lipase deficiency; LPLD) or lipodystrophies are highly limited and often inadequate. Volanesorsen, an ASO to apolipoprotein C-3, shows promise in the treatment of LPLD and severe hypertriglyceridaemia as it increases clearance of triglyceride-rich lipoproteins and can normalise triglycerides in these patients. EXPERT OPINION: The uptake of the novel ASO therapies is likely to be limited to selected niche groups or orphan diseases. These will include homozygous FH, severe heterozygous FH for mipomersen; LPLD deficiency and lipodystrophy syndromes for volanesorsen and treatment of patients with high elevated Lp(a) levels.
Assuntos
Anticolesterolemiantes/uso terapêutico , Hiperlipidemias/tratamento farmacológico , Oligonucleotídeos Antissenso/uso terapêutico , Animais , Apolipoproteína B-100/imunologia , Apolipoproteína B-100/metabolismo , Humanos , Hiperlipidemias/imunologia , Hiperlipidemias/metabolismo , Hiperlipoproteinemia Tipo I/tratamento farmacológico , Hiperlipoproteinemia Tipo I/imunologia , Hiperlipoproteinemia Tipo I/metabolismo , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Hiperlipoproteinemia Tipo II/imunologia , Hiperlipoproteinemia Tipo II/metabolismo , Hipertrigliceridemia/tratamento farmacológico , Hipertrigliceridemia/imunologia , Hipertrigliceridemia/metabolismo , Oligonucleotídeos/uso terapêutico , Resultado do TratamentoRESUMO
CONTEXT: Among type V hyperlipoproteinemias, only one-fourth of the patients have genetic defects in lipoprotein lipase (LPL) or in its associated molecules; the exact mechanism in other patients is usually unknown. OBJECTIVE: The aim of the study was to report a case of severe hypertriglyceridemia induced by anti-apolipoprotein (apo) C-II autoantibody and to clarify its pathogenesis. SUBJECT AND METHODS: A 29-year-old Japanese woman presented with severe persistent hypertriglyceridemia since the age of 20 years. The past history was negative for acute pancreatitis, eruptive xanthomas, or lipemia retinalis. LPL mass and activities were normal. Plasma apo C-II levels were extremely low, but no mutation was observed in APOC2. RESULTS: Apo C-II protein was detected in the serum by immunoprecipitation and Western blotting. Large amounts of IgG and IgM were incorporated with apo C-II protein coimmunoprecipitated by anti-apo C-II antibody. IgG, but not IgM, purified from the serum prevented interaction of apo C-II with lipid substrate and diminished LPL hydrolysis activity. CONCLUSION: We identified anti-apo C-II antibody in a myeloma-unrelated severe hypertriglyceridemic patient. In vitro analysis confirmed that the autoantibody disrupted the interaction between apo C-II and lipid substrate, suggesting the etiological role of anti-apo C-II antibody in severe hypertriglyceridemia in this patient.
Assuntos
Apolipoproteína C-II/imunologia , Autoanticorpos/sangue , Doenças Autoimunes/imunologia , Hipertrigliceridemia/imunologia , Adulto , Doenças Autoimunes/sangue , Feminino , Humanos , Hipertrigliceridemia/sangueRESUMO
Obesity is a chronic inflammatory state characterized by infiltration of adipose tissue by immune cell populations, including T lymphocytes. Natural killer T (NKT) cells, a specialized lymphocyte subset recognizing lipid antigens, can be pro- or anti-inflammatory. Their role in adipose inflammation continues to be inconclusive and contradictory. In obesity, the infiltration of tissues by invariant NKT (iNKT) cells is decreased. We therefore hypothesized that an excess iNKT cell complement might improve metabolic abnormalities in obesity. Vα14 transgenic (Vα14tg) mice, with increased iNKT cell numbers, on a LDL receptor-deficient (Ldlr(-/-)) background and control Ldlr(-/-) mice were placed on an obesogenic diet for 16 weeks. Vα14tg.Ldlr(-/-) mice gained 25% more weight and had increased adiposity than littermate controls. Transgenic mice also developed greater dyslipidemia, hyperinsulinemia, insulin resistance, and hepatic triglyceride accumulation. Increased macrophage Mac2 immunostaining and proinflammatory macrophage gene expression suggested worsened adipose inflammation. Concurrently, these mice had increased atherosclerotic lesion area and aortic inflammation. Thus, increasing the complement of iNKT cells surprisingly exacerbated the metabolic, inflammatory, and atherosclerotic features of obesity. These findings suggest that the reduction of iNKT cells normally observed in obesity may represent a physiological attempt to compensate for this inflammatory condition.
Assuntos
Aterosclerose/imunologia , Células T Matadoras Naturais/imunologia , Obesidade/imunologia , Tecido Adiposo Branco/imunologia , Adiposidade , Animais , Aorta/imunologia , Aorta/patologia , Aterosclerose/etiologia , Aterosclerose/metabolismo , Contagem de Linfócito CD4 , Dieta Hiperlipídica/efeitos adversos , Fígado Gorduroso/etiologia , Fígado Gorduroso/imunologia , Fígado Gorduroso/metabolismo , Hipercolesterolemia/etiologia , Hipercolesterolemia/imunologia , Hipercolesterolemia/metabolismo , Hipertrigliceridemia/etiologia , Hipertrigliceridemia/imunologia , Hipertrigliceridemia/metabolismo , Macrófagos/imunologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Camundongos Obesos , Obesidade/etiologia , Obesidade/metabolismo , Sacarose/efeitos adversosRESUMO
PURPOSE: Biological effects of marine oils, fish oil (FO) and krill oil (KO), are mostly attributed to the high content of n-3 polyunsaturated fatty acids (n-3 PUFAs), predominantly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The study was aimed to investigate the influence of FO and KO on lipid homeostasis and inflammation in an animal model of persistent low-grade exposure to human tumor necrosis factor α (hTNF-α) and to evaluate whether these effects depend on the structural forms of EPA and DHA [triacylglycerols (TAG) vs. phospholipids]. METHODS: Male C57BL/6 hTNF-α mice were fed for 6 weeks a high-fat control diet (24.50 % total fats, w/w) or high-fat diets containing either FO or KO at similar doses of n-3 PUFAs (EPA: 5.23 vs. 5.39 wt%, DHA: 2.82 vs. 2.36 wt% of total fatty acids). RESULTS: We found that KO, containing bioactive n-3 PUFAs in the form of phospholipids, was capable of modulating lipid metabolism by lowering plasma levels of TAG and cholesterol and stimulating the mitochondrial and peroxisomal fatty acid ß-oxidation, as well as improving the overall carnitine turnover. Though the administration of FO was not as effective as KO in the lowering of plasma TAG, FO significantly improved the levels of all cholesterol classes in plasma. Except from the increase in the levels of IL-17 in FO-fed mice and a trend to decrease in MCP-1 levels in KO-fed animals, the levels of pro-inflammatory cytokines were not substantially different between treatment groups. CONCLUSION: Our findings demonstrate that FO and KO are comparable dietary sources of n-3 PUFAs. However, when quantitatively similar doses of n-3 PUFAs are administered, KO seems to have a greater potential to promote lipid catabolism. The effect of dietary oils on the levels of inflammatory markers in hTNF-α transgenic mice fed a high-fat diet needs further investigations.
Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Euphausiacea/química , Óleos de Peixe/uso terapêutico , Hipertrigliceridemia/prevenção & controle , Hipolipemiantes/uso terapêutico , Metabolismo dos Lipídeos , Óleos/uso terapêutico , Animais , Carnitina/sangue , Carnitina/metabolismo , Citocinas/metabolismo , Suplementos Nutricionais , Ácidos Docosa-Hexaenoicos/administração & dosagem , Ácidos Docosa-Hexaenoicos/sangue , Ácidos Docosa-Hexaenoicos/metabolismo , Ácidos Docosa-Hexaenoicos/uso terapêutico , Ácido Eicosapentaenoico/administração & dosagem , Ácido Eicosapentaenoico/sangue , Ácido Eicosapentaenoico/metabolismo , Ácido Eicosapentaenoico/uso terapêutico , Humanos , Hipertrigliceridemia/sangue , Hipertrigliceridemia/etiologia , Hipertrigliceridemia/imunologia , Fígado/imunologia , Fígado/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Fosfolipídeos/sangue , Fosfolipídeos/metabolismo , Triglicerídeos/sangue , Triglicerídeos/metabolismo , Fator de Necrose Tumoral alfa/biossíntese , Fator de Necrose Tumoral alfa/genética , Fator de Necrose Tumoral alfa/metabolismoRESUMO
Insulin plays a central role in regulating energy metabolism, including hepatic transport of very low-density lipoprotein (VLDL)-associated triglyceride. Hepatic hypersecretion of VLDL and consequent hypertriglyceridemia leads to lower circulating high-density lipoprotein levels and generation of small dense low-density lipoproteins characteristic of the dyslipidemia commonly observed in metabolic syndrome and type 2 diabetes mellitus. Physiological fluctuations of insulin modulate VLDL secretion, and insulin inhibition of VLDL secretion upon feeding may be the first pathway to become resistant in obesity that leads to VLDL hypersecretion. This review summarizes the role of insulin-related signaling pathways that determine hepatic VLDL production. Disruption in signaling pathways that reduce generation of the second messenger phosphatidylinositide (3,4,5) triphosphate downstream of activated phosphatidylinositide 3-kinase underlies the development of VLDL hypersecretion. As insulin resistance progresses, a number of pathways are altered that further augment VLDL hypersecretion, including hepatic inflammatory pathways. Insulin plays a complex role in regulating glucose metabolism, and it is not surprising that the role of insulin in VLDL and lipid metabolism will prove equally complex.
Assuntos
Hipertrigliceridemia/etiologia , Resistência à Insulina , Insulina/metabolismo , Lipoproteínas VLDL/biossíntese , Fígado/metabolismo , Animais , Apolipoproteínas B/genética , Apolipoproteínas B/metabolismo , Glicemia/metabolismo , Citocinas/metabolismo , Metabolismo Energético , Humanos , Hipertrigliceridemia/genética , Hipertrigliceridemia/imunologia , Hipertrigliceridemia/metabolismo , Hipertrigliceridemia/fisiopatologia , Mediadores da Inflamação/metabolismo , Fígado/imunologia , Fígado/fisiopatologia , Fosfatidilinositol 3-Quinase/metabolismo , Fosfatos de Fosfatidilinositol/metabolismo , Transdução de Sinais , Regulação para CimaRESUMO
The aim of this study was to investigate the association between leukocyte subtype counts and hyper-LDL cholesterolemia, hypertriglyceridemia, and hypo-HDL cholesterolemia. Logistic regressions using hyper-LDL cholesterolemia, hypertriglyceridemia, and hypo-HDL cholesterolemia as a dependent variable and total leukocyte, basophil, eosinophil, neutrophil, lymphocyte, and monocyte counts as an independent variable were calculated adjusting for age, body mass index (BMI), high-sensitivity C-reactive protein (hs-CRP), smoking, drinking, and physical activity in apparently healthy Japanese men (1,803) and women (1,150). The odds ratio (OR) of hyper-LDL cholesterolemia for total leukocyte, eosinophil, and lymphocyte counts, the OR of hypertriglyceridemia for total leukocyte, eosinophil, neutrophil, and lymphocyte counts, and the OR of hypo-HDL cholesterolemia for total leukocyte, neutrophil, and lymphocyte counts were significant in men, and the OR of hyper-LDL cholesterolemia, for lymphocyte count, and the OR of hypo-HDL cholesterolemia for eosinophil count were significant in women. Lymphocyte count was significantly associated with hyper-LDL cholesterolemia independently of hs-CRP in apparently healthy Japanese.
Assuntos
Povo Asiático , Proteína C-Reativa/análise , LDL-Colesterol/sangue , Hiperlipoproteinemia Tipo II/sangue , Contagem de Linfócitos , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , HDL-Colesterol/sangue , Estudos Transversais , Feminino , Humanos , Hiperlipoproteinemia Tipo II/etnologia , Hiperlipoproteinemia Tipo II/imunologia , Hipertrigliceridemia/sangue , Hipertrigliceridemia/etnologia , Hipertrigliceridemia/imunologia , Hipolipoproteinemias/sangue , Hipolipoproteinemias/etnologia , Hipolipoproteinemias/imunologia , Japão , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Razão de Chances , Valor Preditivo dos Testes , Medição de Risco , Fatores de Risco , Triglicerídeos/sangue , Regulação para Cima , Adulto JovemRESUMO
PURPOSE: The aim of this study was to compare the effects of fibrates and omega-3 fatty acids on lymphocyte secretory function and systemic inflammation in patients with isolated hypertriglyceridemia. METHODS: The study included 107 patients with isolated hypertriglyceridemia who received bezafibrate (200 mg twice daily), omega-3 fatty acids (1 g twice daily) or placebo for 12 weeks. The lipid profile, fasting and 2-h post-glucose load plasma glucose levels, homeostasis model assessment index (HOMA), plasma high-sensitivity C-reactive protein (hsCRP) levels and lymphocyte release of interleukin-2, interferon-γ and tumor necrosis factor-α were assessed at baseline, on the day of randomization, and after 4 and 12 weeks of treatment. RESULTS: Both bezafibrate and omega-3 fatty acids reduced plasma triglyceride levels. Bezafibrate additionally decreased total and low-density lipoprotein-cholesterol levels and the HOMA and insignificantly decreased post-glucose load plasma glucose, as well as increased high-density lipoprotein-cholesterol. Bezafibrate treatment was associated with a reduction in lymphocyte release of interleukin-2, interferon-γ and tumor necrosis factor-α, which was accompanied by a reduction in plasma hsCRP levels. Omega-3 fatty acid did not significantly reduce lymphocyte cytokine release and plasma hsCRP. The anti-inflammatory effects of both drugs did not correlate with their action on plasma lipids, but in the case of the former the effect was related to the improvement in insulin sensitivity. CONCLUSION: Our results indicate that bezafibrate is superior to omega-3 fatty acid in inhibiting systemic inflammation and lymphocyte secretory function.
Assuntos
Bezafibrato/uso terapêutico , Citocinas/metabolismo , Ácidos Graxos Ômega-3/uso terapêutico , Hipertrigliceridemia/tratamento farmacológico , Hipolipemiantes/uso terapêutico , Inflamação/sangue , Linfócitos/efeitos dos fármacos , Adulto , Idoso , Bezafibrato/administração & dosagem , Bezafibrato/efeitos adversos , Proteína C-Reativa/metabolismo , Colesterol/sangue , Ácidos Graxos Ômega-3/administração & dosagem , Ácidos Graxos Ômega-3/efeitos adversos , Feminino , Humanos , Hipertrigliceridemia/sangue , Hipertrigliceridemia/imunologia , Hipolipemiantes/administração & dosagem , Hipolipemiantes/efeitos adversos , Inflamação/imunologia , Linfócitos/imunologia , Linfócitos/metabolismo , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Triglicerídeos/sangueRESUMO
BACKGROUND: Smoking is associated with increased postprandial hypertriglyceridemia (PPT). Inflammation and insulin resistance are potential "drivers" for this phenomenon. We tested whether inflammatory patterns and/or insulin resistance explain the effect of smoking on PPT. METHODS AND RESULTS: Men and women in the NHLBI Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN) study (n=1036, age 49+/-16y) were included. Each participant was asked to suspend use of lipid-lowering drugs for 3 weeks and was given a high-fat milkshake (83% fat and 700kcal/m(2)). Triglyceride concentrations at 0, 3.5 and 6h after the fat load were measured. Inflammatory markers were measured at baseline. Principal component analysis was used to derive inflammatory patterns from individual inflammatory markers (hsCRP, IL2 soluble receptor-alpha, IL6, TNF-alpha and MCP1). Insulin resistance (IR) was estimated using the HOMA equation. Repeated measures-ANOVA was used for analyses. Two inflammatory patterns, namely CRP-IL6 pattern and MCP1-TNF-alpha pattern, were derived. We found significant main (smoking and time) and interaction (smokingxtime) effects (P<0.01) for triglycerides. The multivariate-adjusted triglyceride (mg/dL) concentrations (mean+/-S.E.M.) for never, past and current smokers were 127.38+/-1.04, 119.82+/-1.05 and 134.92+/-1.08 at 0h; 229.42+/-1.04, 238.39+/-1.05 and 293.94+/-1.08 at 3.5h; and 194.63+/-1.04, 208.38+/-1.05 and 248.27+/-1.08 at 6h after the fat load, respectively. Smoking remained significant after adjusting for HOMA-IR and/or inflammatory patterns which showed independent associations with PPT (P<0.05). CONCLUSIONS: These data confirm impaired metabolism of fat among smokers and suggest that mechanisms other than inflammation or insulin resistance may explain the observed hypertriglyceridemia among smokers.
Assuntos
Hipertrigliceridemia/imunologia , Hipertrigliceridemia/metabolismo , Inflamação/microbiologia , Adulto , Idoso , Gorduras na Dieta , Feminino , Humanos , Resistência à Insulina , Ligantes , Masculino , Pessoa de Meia-Idade , Estresse Oxidativo , Receptores Ativados por Proliferador de Peroxissomo/metabolismo , Fenótipo , Período Pós-Prandial , Fumar , Triglicerídeos/metabolismoRESUMO
INTRODUCTION: Post-prandial hypertriglyceridaemia is a risk factor for cardiovascular disease, although the underlying mechanisms remain unclear. High density lipoproteins (HDL) have been shown to be atheroprotective, in part through attenuation of vascular inflammation. In this study, the influence of acute hypertriglyceridaemia on the composition and anti-inflammatory properties of HDL was investigated. METHODS: Eight fasting healthy male subjects (34+/-2 years) received 20% Intralipid (15 mg/kg/h) or saline, on separate occasions in random order. At baseline and 60 min post-infusion, the total HDL fraction was isolated and its chemical composition determined. HDL were added to TNF-alpha stimulated human coronary artery endothelial cells and VCAM-1 and ICAM-1 expression was determined by flow cytometry. RESULTS: Serum triglyceride (97.4+/-8.5mg/dL baseline, 283.2+/-35.4 mg/dL post-infusion, p<0.001) and HDL triglyceride content (3.8+/-0.5% HDL mass baseline, 5.3+/-0.9% HDL mass post-infusion, p<0.05) increased significantly after Intralipid infusion. HDL post-Intralipid were significantly less anti-inflammatory compared with control (e.g. at 8 microM apoA-I, %VCAM-1 expression 54+/-5 post-saline, 73+/-4 post-Intralipid, p=0.01; %ICAM-1 expression 94+/-1 post-saline, 99.4+/-0.6 post-Intralipid, p<0.01). There was also a significant correlation between HDL triglyceride content and VCAM-1 expression (R=0.70, p=0.005); as well as between plasma triglyceride levels and both VCAM-1 (R=0.71, p<0.005) and ICAM-1 expression (R=0.80, p<0.005). CONCLUSION: Acute hypertriglyceridaemia, simulating the post-prandial state, results in triglyceride-rich HDL with impaired anti-inflammatory capacity.
Assuntos
Hipertrigliceridemia/sangue , Inflamação/prevenção & controle , Lipoproteínas HDL/sangue , Triglicerídeos/sangue , Doença Aguda , Adulto , Apolipoproteína A-I/sangue , Células Cultivadas , Células Endoteliais/imunologia , Células Endoteliais/metabolismo , Emulsões Gordurosas Intravenosas/administração & dosagem , Humanos , Hipertrigliceridemia/imunologia , Inflamação/sangue , Inflamação/imunologia , Mediadores da Inflamação/sangue , Infusões Intravenosas , Molécula 1 de Adesão Intercelular/metabolismo , Masculino , Período Pós-Prandial , Distribuição Aleatória , Fator de Necrose Tumoral alfa/metabolismo , Regulação para Cima , Molécula 1 de Adesão de Célula Vascular/metabolismoAssuntos
Pressão Sanguínea/efeitos dos fármacos , Citocinas/sangue , Fenofibrato/uso terapêutico , Hipertrigliceridemia/tratamento farmacológico , Hipolipemiantes/uso terapêutico , Proteína C-Reativa/análise , Feminino , Humanos , Hipertrigliceridemia/imunologia , Hipertrigliceridemia/fisiopatologia , Interleucina-6/sangue , Masculino , PPAR alfa/fisiologia , Fator de Necrose Tumoral alfa/análiseRESUMO
Multiple eruptive dermatofibromas (MEDF) are rare and have been thought to be associated with altered immunity. It has been reported that dermatofibromas (DFs) are positive for factor X IIIa but not for CD34. In this report, we describe a 34-year-old Japanese woman with MEDF and persistent hypertriglyceridemia. Histopathological examination revealed that several areas in larger nodules, showing higher cellularity and storiform growth pattern, had CD34+ cells. Our case and the review of previous reports suggest that hyperlipidemia, including hypertriglyceridemia, could induce MEDF and that highly cellular areas in DFs are sometimes positive for CD34.
Assuntos
Histiocitoma Fibroso Benigno/patologia , Hipertrigliceridemia/diagnóstico , Neoplasias Cutâneas/patologia , Adulto , Antígenos CD34/imunologia , Biópsia por Agulha , Feminino , Seguimentos , Histiocitoma Fibroso Benigno/complicações , Histiocitoma Fibroso Benigno/imunologia , Humanos , Hipertrigliceridemia/complicações , Hipertrigliceridemia/imunologia , Imuno-Histoquímica , Medição de Risco , Neoplasias Cutâneas/complicações , Neoplasias Cutâneas/imunologiaRESUMO
Excessive supply of lipids to the organism of rats causes increase in lipid peroxidation, reduction of red cell energy status, the appearance in them of immunosuppressive properties, and inhibition of immunological reactivity. Administration of beta-carotene and essential corrects the biochemical status and immunological reactivity of the organism in alimentary lipid loading. beta-Carotene cancels the immunosuppressive properties of light red blood cells, whereas essential induces the appearance of immunostimulating properties in the heavy cells.
Assuntos
Adjuvantes Imunológicos/uso terapêutico , Antioxidantes/uso terapêutico , Hipertrigliceridemia/tratamento farmacológico , Fosfatidilcolinas/uso terapêutico , beta Caroteno/uso terapêutico , Animais , Células Produtoras de Anticorpos/efeitos dos fármacos , Células Produtoras de Anticorpos/imunologia , Gorduras na Dieta/administração & dosagem , Metabolismo Energético/efeitos dos fármacos , Eritrócitos/efeitos dos fármacos , Eritrócitos/metabolismo , Hipertrigliceridemia/sangue , Hipertrigliceridemia/etiologia , Hipertrigliceridemia/imunologia , Imunização/métodos , Peroxidação de Lipídeos/efeitos dos fármacos , Ratos , Ratos Wistar , Baço/efeitos dos fármacos , Baço/imunologia , Fatores de TempoRESUMO
Triglyceride-rich lipoproteins can inhibit endotoxin activity in vitro and in rodents. We sought to determine whether Intralipid, a triglyceride-rich fat emulsion which in contact with plasma functions similarly to endogenous lipoproteins, can alter the human response to endotoxin. Intralipid inhibited endotoxin-induced cytokine production in human whole blood in vitro in a dose-dependent manner, with maximal inhibition (up to 70%) being achieved at a concentration of 10 g/liter. In healthy men, a bolus intravenous injection of endotoxin (lot EC-5; 20 U/kg of body weight) was given midway through a 4-h infusion (125 ml/h) of either 5% glucose (n = 5) or 20% Intralipid (n = 5). The infusion of Intralipid led to an increase in triglyceride levels in serum from 95 +/- 16 to 818 +/- 135 mg/dl prior to endotoxin administration, i.e., levels that importantly reduced cytokine production in endotoxin-stimulated whole blood. However, in vivo hypertriglyceridemia did not influence inflammatory responses to endotoxin (fever, release of tumor necrosis factor and soluble tumor necrosis factor receptors, and leukocytosis) or even potentiated endotoxin responses (release of interleukins 6 and 8 and neutrophil degranulation). Hypertriglyceridemia does not inhibit the in vivo responses to endotoxin in humans.
Assuntos
Hipertrigliceridemia/imunologia , Lipopolissacarídeos/toxicidade , Adulto , Citocinas/biossíntese , Emulsões Gordurosas Intravenosas/farmacologia , Humanos , Contagem de Leucócitos , MasculinoRESUMO
A 41-year-old female patient with muscle dystrophy, hepatosplenomegaly and tendinous xanthoma showed mild hypertriglyceridemia. The lipoprotein profile in blood showed increases in triglycerides in VLDL and LDL, and a marked decrease of cholesterol in HDL. Chylomicronemia was found, but was not severe. Both lipoprotein lipase and hepatic triglyceride lipase activities were reduced to a level that was only a few percent of the control. Immunoblotting study revealed that the IgG autoantibody in her serum was apparently reactable with hepatic triglyceride lipase and weakly with lipoprotein lipase. Hypertriglyceridemia in this patient is suggested to be due to the autoantibody to these lipases.
Assuntos
Autoanticorpos/imunologia , Hipertrigliceridemia/imunologia , Lipase Lipoproteica/imunologia , Adulto , Feminino , Humanos , Hipertrigliceridemia/sangue , Imunoglobulina G/imunologia , Lipoproteínas/sangueRESUMO
Multifactorial analysis of effects of metabolic and endocrine determinants of the host and morphology of the tumor on cellular immunity has been undertaken in 29 patients with cancer of the corpus uteri. Several regression models obtained using the Hocking-Leslie method demonstrated significant effects of age, obesity, triglyceride levels, morphologic differentiation of the tumor and magnitude of invasion on various levels of cellular immunity, presenting as an increase in T-helper and decrease in suppressor counts. The multifactorial analysis depicted additive effects of endocrine homeostatic determinants and the tumor on different aspects of cellular immunity in cancer of the corpus uteri.